Regeneron Pharmaceuticals, Inc. (REGN)
- Previous Close
547.67 - Open
549.00 - Bid 526.44 x 100
- Ask 528.55 x 100
- Day's Range
527.13 - 552.84 - 52 Week Range
525.99 - 1,211.20 - Volume
1,424,982 - Avg. Volume
1,100,382 - Market Cap (intraday)
56.982B - Beta (5Y Monthly) 0.43
- PE Ratio (TTM)
13.42 - EPS (TTM)
39.32 - Earnings Date Jul 30, 2025 - Aug 4, 2025
- Forward Dividend & Yield 3.52 (0.67%)
- Ex-Dividend Date May 20, 2025
- 1y Target Est
800.13
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
www.regeneron.comRecent News: REGN
View More
Performance Overview: REGN
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: REGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: REGN
View MoreValuation Measures
Market Cap
56.98B
Enterprise Value
51.34B
Trailing P/E
13.42
Forward P/E
15.15
PEG Ratio (5yr expected)
1.14
Price/Sales (ttm)
4.28
Price/Book (mrq)
1.94
Enterprise Value/Revenue
3.64
Enterprise Value/EBITDA
9.29
Financial Highlights
Profitability and Income Statement
Profit Margin
31.94%
Return on Assets (ttm)
6.91%
Return on Equity (ttm)
15.96%
Revenue (ttm)
14.09B
Net Income Avi to Common (ttm)
4.5B
Diluted EPS (ttm)
39.32
Balance Sheet and Cash Flow
Total Cash (mrq)
8.35B
Total Debt/Equity (mrq)
9.20%
Levered Free Cash Flow (ttm)
2.08B
Research Analysis: REGN
View MoreResearch Reports: REGN
View MoreRegeneron Earnings: Revenue Contraction Driven by Declining Eylea Sales
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
RatingPrice TargetRegeneron Earnings: Pressure On Eylea Franchise Weighs on Investor Sentiment; Shares Undervalued
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
RatingPrice TargetRegeneron Earnings: Pressure On Eylea Franchise Weighs on Investor Sentiment; Shares Undervalued
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
RatingPrice TargetCompany initiates first-ever dividend program
Regeneron is a biopharmaceutical company focused on treatments for eye diseases, cancer, dermatitis, and rheumatoid arthritis. Founded in 1988, Regeneron has collaborated with Amgen, Procter & Gamble, Bayer, Sanofi, and Japan's Sumitomo Chemical. The company is a component of the S&P 500, has more than 15,100 employees worldwide, and is based in Tarrytown, New York.
RatingPrice Target